摘要
目的观察卡培他滨联合奥沙利铂(CapeOX)、替吉奥联合奥沙利铂(SOX)及替吉奥单药新辅助化疗方案在进展期胃癌术前的应用效果,并分析其对基质金属蛋白酶-9 (MMP-9)、血管内皮生长因子(VEGF)水平的影响。方法选取2018年1月至2019年12月西安市长安区医院诊治的拟行胃癌手术的150例进展期胃癌患者为研究对象。按照随机数表法将患者均分为Cape OX组、SOX组和替吉奥单药组各50例。手术前后共化疗8个周期,比较三组患者的临床疗效、化疗前后MMP-9、VEGF水平,并分析三组患者的不良反应状况及1年生存率。结果 Cape OX组、SOX组患者的客观缓解率和临床获益率分别为58.00%、88.00%和62.00%、92.00%,明显高于替吉奥单药组的38.00%、58.00%,差异均有统计学意义(P<0.05),而Cape OX组和SOX组患者的客观缓解率和临床获益率比较差异均无统计学意义(P>0.05);化疗8个周期后,三组患者的MMP-9、VEGF水平明显低于化疗前,且Cape OX组、SOX组患者的MMP-9、VEGF水平分别为(82.24±19.15) ng/m L、(86.16±20.35) pg/m L和(79.43±18.24) ng/m L、(83.39±19.56) pg/m L,明显低于替吉奥单药组的(102.54±23.01) ng/mL、(114.52±27.34) pg/mL,差异均有统计学意义(P<0.05),而CapeOX组和SOX组患者化疗8个周期后的MMP-9、VEGF水平比较差异均无统计学意义(P>0.05);CapeOX组和SOX组患者的不良反应总发生率分别为40.00%、36.00%,明显低于替吉奥单药组的60.00%,差异有统计学意义(P<0.05),而CapeOX组和SOX组比较差异无统计学意义(P>0.05);CapeOX组和SOX组患者的1年生存率分别为82.00%、86.00%,明显高于替吉奥单药组的56.00%,差异有统计学意义(P<0.05),而CapeOX组和SOX组比较差异无统计学意义(P>0.05)。结论 CapeOX及SOX新辅助化疗方案在进展期胃癌患者术前的应用均能明显提高患者的客观缓解率和临床获益率,降低MMP-9、VEGF水平,临床应用效果显著,值得推广应用。
Objective To observe the effect of capecitabine combined with oxaliplatin(CAPEOX),tegafur combined with oxaliplatin(SOX),and tegafur monotherapy neoadjuvant chemotherapy regimen in preoperative treatment of advanced gastric cancer,and to analyze its effects on the levels of matrix metalloproteinase-9(MMP-9) and vascular endothelial growth factor(VEGF).Methods A total of 150 patients with advanced gastric cancer who planned to undergo gastric cancer surgery in Xi’an Chang’an District Hospital from January 2018 to December 2019 were selected as the research subjects.According to random number table method,the patients were randomly divided into CapeOX group,SOX group,and tegafur monotherapy group,with 50 cases in each group.A total of 8 cycles of chemotherapy were performed before and after surgery,the clinical efficacy,the levels of MMP-9 and VEGF before and after chemotherapy were compared among the three groups,and the adverse reactions and 1-year survival rate of the three groups were analyzed.Results The objective response rate and clinical benefit rate in CapeOX group and SOX group were58.00%,88.00% and 62.00%,92.00%,respectively,which were significantly higher than corresponding 38.00%,58.00% in the tegafur monotherapy group,and the differences were statistically significant(all P<0.05).However,there were no significant difference in objective response rate and clinical benefit rate between CapeOX group and SOX group(P>0.05);after 8 cycles of chemotherapy,the levels of MMP-9 and VEGF in three groups were significantly lower than before chemotherapy,and the levels of MMP-9 and VEGF in Cape OX group and SOX group were(82.24±19.15) ng/m L,(86.16±20.35) pg/mL and(79.43±18.24) ng/mL,(83.39±19.56) pg/mL,respectively,which were significantly lower than corresponding(102.54 ± 23.01) ng/mL,(114.52 ± 27.34) pg/mL in the tegafur monotherapy group,and the differences were statistically significant(all P<0.05).However,there were no significant difference in MMP-9 and VEGF levels between CapeOX group and SOX gro
作者
陈怡
曹强
杨佳员
高成栋
卓飞
CHEN Yi;CAO Qiang;YANG Jia-yuan;GAO Cheng-dong;ZHUO Fei(Department of General Surgery,Xi’an Changan District Hospital,Xi'an 710100,Shaanxi,CHINA)
出处
《海南医学》
CAS
2021年第23期3028-3031,共4页
Hainan Medical Journal
关键词
进展期胃癌
新辅助化疗
奥沙利铂
卡培他滨
替吉奥
基质金属蛋白酶-9
血管内皮生长因子
Advanced gastric cancer
Neoadjuvant chemotherapy
Oxaliplatin
Capecitabine
Tegafur
Matrix metalloproteinase-9(MMP-9)
Vascular endothelial growth factor(VEGF)
